ASH 2009 meeting report-Top 10 clinically oriented abstracts in acute leukemia

Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

Prognostic markers, such as NPM1, Flt3-ITD, and cytogenetic abnormalities have made it possible to formulate aggressive treatment plans for unfavorable acute myeloid leukemia (AML). However, the long-term survival of AML with unfavorable factors remains unsatisfactory. The latest data indicate that the standard dose of daunorubicin (DNR) at 45 mg/m2 is inferior to high dose 90 mg/m2 for inducti...

2005–2009 ASCB Annual Meeting abstracts

Metastatic Melanoma (Secondary Malignancy) after Recovery from Acute Lymphoblastic Leukemia in a 10-year-old Girl: a case report

Acute lymphoblastic leukemia is the most common malignancy in children with a 5-year survival rate, accounting for 80% of cases. Melanoma is rare in children and has been reported as a sporadically occurring secondary malignant neoplasm in children with acute lymphoblastic leukemia. This study presented a 10-year-old Iranian child with pre-B-cell acute lymphoblastic leukemia that was diagnosed ...

Report of the 91st Annual Meeting of the Endocrine Society, Washington, DC – JUNE 10 -13, 2009

TEXT NOT PROVIDED

AAPM Annual Meeting Abstracts

AAPM Annual Meeting Abstracts